Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

ClinicalTrials.gov ID: NCT04783389

Public ClinicalTrials.gov record NCT04783389. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate CBP-201 in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Study identification

NCT ID
NCT04783389
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Connect Biopharm LLC
Industry
Enrollment
40 participants

Conditions and interventions

Interventions

  • CBP-201 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 15, 2021
Primary completion
Apr 14, 2022
Completion
Jun 9, 2022
Last update posted
Oct 16, 2023

2021 – 2022

United States locations

U.S. sites
32
U.S. states
19
U.S. cities
29
Facility City State ZIP Site status
Connect Investigative Site 130 Birmingham Alabama 35205
Connect Investigative Site 124 Bakersfield California 93301
Connect Investigative Site 125 La Mesa California 91942
Connect Investigative Site 134 Los Angeles California 90048
Connect Investigative Site 128 Temecula California 92592
Connect Investigative Site 119 Torrance California 90503
Connect Investigative Site 114 Miami Florida 33135
Connect Investigative Site 109 Miami Florida 33155
Connect Investigative Site 116 Tampa Florida 33613
Connect Investigative Site 111 Chicago Illinois 60637
Connect Investigative Site 126 Chicago Illinois 60657
Connect Investigative Site 132 Louisville Kentucky 40205
Connect Investigative Site 110 White Marsh Maryland 21162
Connect Investigative Site 121 Ann Arbor Michigan 48109-0360
Connect Investigative Site 127 St Louis Missouri 63141
Connect Investigative Site 102 Princeton New Jersey 08540
Connect Investigative Site 105 Rochester New York 14618
Connect Investigative Site 113 The Bronx New York 10461
Connect Investigative Site 117 Winston-Salem North Carolina 27103
Connect Investigative Site 123 Cincinnati Ohio 45229
Connect Investigative Site 133 Columbus Ohio 43235
Connect Investigative Site 112 Tulsa Oklahoma 74136
Connect Investigative Site 122 Tulsa Oklahoma 74137
Connect Investigative Site 108 Charleston South Carolina 29425
Connect Investigative Site 107 Memphis Tennessee 38119
Connect Investigative Site 106 Austin Texas 75759
Connect Investigative Site 104 Dallas Texas 75231
Connect Investigative Site 120 Houston Texas 77074
Connect Investigative Site 101 Sherman Texas 75092
Connect Investigative Site 129 St. George Utah 84790
Connect Investigative Site 118 Norfolk Virginia 23507
Connect Investigative Site 115 Bellingham Washington 98225

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04783389, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 16, 2023 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04783389 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →